This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SNMMI 2024
AMA 2024
ASCO 2024
AUA 2024
APCCC 2024
All Conferences
View All
PCF
UroToday Home
Recent Abstracts
Urologic Oncology
Bladder Cancer
Conferences
Recent Abstracts
ASCO 2017: Impact of geographic region on overall survival in patients with metastatic renal cell carcinoma: Results from a pooled clinical trials database
June 4, 2017
ASCO 2017: Effects of pazopanib and sunitinib dose modification on safety and efficacy in patients with metastatic renal cell carcinoma from COMPARZ
June 4, 2017
ASCO 2017: Long-term response and time to response to pazopanib and sunitinib in metastatic renal cell carcinoma: COMPARZ subanalysis
June 4, 2017
ASCO 2017: Penile Cancer: Current Evidence and Controversies
June 4, 2017
ASCO 2017: Safety and usefulness of patient-centered shared survivorship care after chemotherapy for testicular cancer
June 4, 2017
ASCO 2017: FDG PET scan (PET) positive residual lesions after chemotherapy (chemo) for metastatic seminoma: Results of an International Global Germ Cell Cancer Group (G3) registry
June 4, 2017
ASCO 2017: Management Strategies for Nonurothelial Bladder Cancer
June 4, 2017
ASCO 2017: Phase II trial of pembrolizumab in patients (pts) with incurable platinum refractory germ cell tumors (GCT)
June 4, 2017
ASCO 2017: Infusional gemcitabine + docetaxel/melphalan/carboplatin (GemDMC) ± bevacizumab (BEV) as an effective high-dose chemotherapy (HDC) regimen for refractory of poor-risk relapsed germ-cell tumors (GCT)
June 4, 2017
ASCO 2017: Multiregion sequencing of penile cancer to reveal distinct patterns of heterogeneous actionable mutations
June 4, 2017
ASCO 2017: Comprehensive genomic profiling (CGP) of advanced papillary renal cell carcinoma (PRCC) to reveal distinctions from TCGA dataset
June 4, 2017
ASCO 2017: Checkpoint inhibitors in metastatic renal cell carcinoma patients including elderly subgroups: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
June 4, 2017
ASCO 2017: Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC)
June 4, 2017
ASCO 2017: Safety and efficacy of nivolumab for metastatic renal cell carcinoma (mRCC): Real world data from an Italian expanded access program (EAP)
June 4, 2017
ASCO 2017: Phase II study of pazopanib in patients with von Hippel-Lindau disease
June 4, 2017
ASCO 2017: Epacadostat plus pembrolizumab in patients with advanced RCC: Preliminary phase I/II results from ECHO-202/KEYNOTE-037
June 4, 2017
ASCO 2017: Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer
June 4, 2017
ASCO 2017: Phase II study of alternate sunitinib schedule in patients with metastatic renal cell carcinoma
June 4, 2017
ASCO 2017: Genomic Selection for Prostate Cancer: Are We Ready?
June 4, 2017
ASCO 2017: Interpreting Biomarkers and Trial Outcomes: How Confident Are We?
June 4, 2017
Page 444 of 575
Start
Prev
439
440
441
442
443
444
445
446
447
448
Next
End
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free